Achieve life sciences announces presentation of cytisinicline e-cigarette cessation (orca-v1) results at society for research on nicotine and tobacco europe (srnt-e) annual meeting

Seattle and vancouver, british columbia, sept. 11, 2023 (globe newswire) -- achieve life sciences, inc. (nasdaq: achv), a late-stage clinical pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that phase 2 orca-v1 trial results will be presented at the society for research on nicotine and tobacco europe (srnt-e) annual meeting, being held in london september 11–13, 2023.
ACHV Ratings Summary
ACHV Quant Ranking